

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



Taurohyodeoxycholic acid-d₄ sodium

Cat. No.: HY-114360AS1 Molecular Formula: $C_{26}H_{45}NO_6S.xNa$

TNF Receptor; Interleukin Related; Isotope-Labeled Compounds Target:

Apoptosis; Immunology/Inflammation; Others Pathway:

Please store the product under the recommended conditions in the Certificate of Storage:

Analysis.

BIOLOGICAL ACTIVITY

Description	Taurohyodeoxycholic acid-d4 (sodium) is a deuterated labeled Taurohyodeoxycholic acid (sodium) ^[1] . Taurohyodeoxycholic acid (THDCA) sodium is the taurine-conjugated form of the secondary bile acid hyodeoxycholic acid. Taurohyodeoxycholic acid can also reduce the activity and expression of myeloperoxidase TNF- α and IL-6, as well as colonic damage in TNBS-induced ulcerative colitis mouse model.
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Taurohyodeoxycholic acid reduces the size and weight of human gallstones in vitro. Taurohyodeoxycholic acid increases bile flow, bile cholesterol secretion and bile lipid secretion in rats. Co-administration of Taurohyodeoxycholic acid and Taurochenodeoxycholic acid prevented Taurohyodeoxycholic acid-induced hepatotoxicity and increased bile flow and bile acid and phospholipid secretion in rats. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Roda A, et al. Taurohyodeoxycholic acid protects against taurochenodeoxycholic acid-induced cholestasis in the rat. Hepatology. 1998 Feb;27(2):520-5.
- [2]. Angelico M, et al. Dissolution of human cholesterol gallstones in bile salt/lecithin mixtures: effect of bile salt hydrophobicity and various pHs. Scand J Gastroenterol. 1995 Dec;30(12):1178-85.
- [3]. Angelico M, et al. Effect of taurohyodeoxycholic acid, a hydrophilic bile salt, on bile salt and biliary lipid secretion in the rat. Dig Dis Sci. 1994 Nov;39(11):2389-97.
- [4]. Solmon Kusuma S, et al. Antineoplastic activity of monocrotaline against hepatocellular carcinoma[J]. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents), 2014, 14(9): 1237-1248.
- [5]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com